EUVIMEDEUVIMED entdecken
Open Access

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer

Fu Gui iD, Baishan Jiang iD, Jie Jiang iD, Zhixiang He iD, Takuya Tsujino iD, Tomoaki Takai, Seiji Arai iD, Celine Pana iD, Jens Köllermann, Gary Andrew Bradshaw iD, Robyn Eisert iD, Marian Kalocsay iD und 4 weitere

Science Advances · 25.04.2025 · 11 (17)

DOI: 10.1126/sciadv.adu0847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 25.04.2025. Verfasst von Fu Gui und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Receptors, Androgen, Cyclin-Dependent Kinases, BRCA1 Protein. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatments for advanced prostate cancer (PCa) primarily target the androgen receptor (AR) pathway. However, the emergence of castration-resistant prostate cancer (CRPC) and resistance to AR pathway inhibitors (APPIs) remains ongoing challenges. Here, we present BSJ-5-63, a proteolysis-targeting chimera (PROTAC) targeting cyclin-dependent kinases (CDKs) CDK12, CDK7, and CDK9, offering a multipronged approach to CRPC therapy. BSJ-5-63 degrades CDK12, diminishing BRCA1 and BRCA2 expression and inducing a sustained “BRCAness” state. This sensitizes cancer cells to PARP inhibitors (PARPis) regardless of their homologous recombination repair (HRR) status. Furthermore, CDK7 and CDK9 degradation attenuates AR signaling, enhancing its therapeutic efficacy. Preclinical studies, including both in vitro and in vivo CRPC models, demonstrate that BSJ-5-63 exerts potent antitumor activity in both AR-positive and AR-negative setting. This study introduces BSJ-5-63 as a promising therapeutic agent that addresses both DNA repair and AR signaling mechanisms, with potential benefits for a board patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsReceptors, AndrogenCyclin-Dependent KinasesBRCA1 ProteinBRCA2 ProteinProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantMaleHumansCell Line, TumorSignal TransductionAnimalsProteolysisMiceCyclin-Dependent Kinase-Activating KinaseXenograft Model Antitumor AssaysCyclin-Dependent Kinase 9

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsReceptors, AndrogenCDK12 protein, humanCyclin-Dependent KinasesBRCA1 ProteinBRCA2 ProteinAR protein, humanCyclin-Dependent Kinase-Activating KinaseCDK7 protein, humanCDK9 protein, human

Autor:innen und Institutionen

  • Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
  • Department of Urology, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.

ORCID-Profile: Fu Gui, Baishan Jiang, Jie Jiang, Zhixiang He, Takuya Tsujino, Seiji Arai, Celine Pana, Gary Andrew Bradshaw, Robyn Eisert, Marian Kalocsay, Anne Fassl, Steven P Balk, Adam S Kibel, Li Jia

Förderung

  • NCI NIH HHS

Zitieren

APA

Gui, F., Jiang, B., Jiang, J., He, Z., Tsujino, T., Takai, T., Arai, S., Pana, C., Köllermann, J., Bradshaw, G. A., Eisert, R., Kalocsay, M., Fassl, A., Balk, S. P., Kibel, A. S., & Jia, L. (2025). Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. Science Advances, 11(17). https://doi.org/10.1126/sciadv.adu0847

Vancouver

Gui F, Jiang B, Jiang J, He Z, Tsujino T, Takai T, et al. Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. Science Advances. 2025;11(17). doi:10.1126/sciadv.adu0847

BibTeX
@article{Gui2025,
  author = {Gui, Fu and Jiang, Baishan and Jiang, Jie and He, Zhixiang and Tsujino, Takuya and Takai, Tomoaki and Arai, Seiji and Pana, Celine and Köllermann, Jens and Bradshaw, Gary Andrew and Eisert, Robyn and Kalocsay, Marian and Fassl, Anne and Balk, Steven P and Kibel, Adam S and Jia, Li},
  title = {Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {17},
  doi = {10.1126/sciadv.adu0847}
}
Kostenlos starten →